表紙
市場調査レポート

薬物検査:技術と世界市場

Drug Testing: Technologies and Global Markets

発行 BCC Research 商品コード 325569
出版日 ページ情報 英文 146 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
薬物検査:技術と世界市場 Drug Testing: Technologies and Global Markets
出版日: 2015年03月09日 ページ情報: 英文 146 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の薬物乱用検査 (DOA) 市場規模は2014年に約28億米ドルとなりました。同市場は今後4.5%のCAGRで拡大し、2019年までにおよそ5億米ドルに達すると予測されています。

当レポートは、世界の薬物乱用検査 (DOA) 市場について調査し、薬物検査技術市場の概要、実績データ・推計およびCAGR予測を含めた世界市場動向の分析、薬剤クラス・地域別の市場分析、主要企業とその主要製品に関する情報、および主要企業のプロファイルをまとめ、お届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 薬物乱用検査の実施

  • シングル vs. マルチパラメーター試験
  • DOAスクリーニング
  • 確認検査
  • 尿検査
  • その他の検査法
    • 血液検査
    • 口腔液検査
    • 唾液検査
    • 汗検査
    • 毛髪検査
  • 検査場所
    • ラボ型DAT
    • ポイントオブケア (POC) DA
    • オンサイト検査 vs. ラボ検査
  • ラボ検査のサンプル型
    • 尿検査
    • 毛髪検査
    • 唾液/口腔液検査
    • 血液検査
    • 汗検査
    • 眼反射
  • 検出期間
  • 薬物検査のごまかし
  • サンプルの有効性
  • 偽陽性・偽陰性
  • 検査技術
    • 免疫測定
    • 酵素免疫測定 (EIA)
    • 固相酵素免疫検定法 (ELISA)
    • 競合的酵素免疫分析法 (EMIT)
    • 蛍光偏光免疫測定法 (FPIA)
    • 放射免疫測定 (RIA)
    • クロマトグラフィー
    • 眼反射測定
  • 第4章 政府規制:麻薬密売・薬物乱用検査
  • 北米
  • 南米
  • 中米・カリブ海諸国
  • 欧州
  • 欧州諸国による薬物禁止の職場規則・法律
  • アジア太平洋

第5章 概要

  • 薬物乱用検査

第6章 世界の薬物乱用検査市場:サンプルマトリックス

  • 薬物乱用検査の売上
  • 世界の尿による薬物乱用検査の売上
  • 世界の血液による薬物乱用検査の売上
  • 世界の口腔液による薬物乱用検査の売上
  • 世界の毛髪による薬物乱用検査の売上
  • 世界の汗による薬物乱用検査の売上
  • 世界のその他のサンプルマトリックスによる薬物乱用検査の売上

第7章 世界の産業構造

  • 地域分析
  • DOA検査・薬物モニタリング市場全体:地域別
  • 成長動向:ラボベース・オンサイトDOA検査市場
  • ラボベース検査

第8章 特許分析

第9章 企業プロファイル

  • ABBOTT LABORATORIES
  • ACON LABORATORIES INC.
  • AGILENT TECHNOLOGIES
  • ALERE INC.
  • AMERICAN BIO MEDICA CORP. (ABMC)
  • BECKMAN COULTER
  • BIO-RAD LABORATORIES, INC
  • CONCATENO, PLC
  • ELITECH GROUP
  • F. HOFFMANN-LA ROCHE LTD.
  • MEDTOX DIAGNOSTICS
  • MICROGENICS
  • NANOGEN INC.
  • OLYMPUS DIAGNOSTICS SYSTEMS
  • ORASURE TECHNOLOGIES INC.
  • ORTHO-CLINICAL DIAGNOSTICS
  • SIEMENS HEALTHCARE DIAGNOSTICS INC.

第10章 付録A

第11章 付録B

図表リスト

目次
Product Code: PHM013F

REPORT HIGHLIGHTS

The global drug of abuse (DOA) testing market reached nearly $2.8 billion in 2014. This market is estimated to grow at a compound annual growth rate (CAGR) of 4.5% to reach almost $3.5 billion by 2019.

This report provides:

  • An overview of the global market for drug testing technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of CAGRs through 2019.
  • An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
  • Information on leading players in the market and their key products.
  • Analysis of leading companies in the field and their successful strategies.

SCOPE OF REPORT

This report contains:

  • An overview of drug abuse trends in terms of various geographic regions as well as drug classes.
  • Drug abuse statistics in key regions.
  • Analysis of regulatory environments in North, South and Central America, Europe, and Asia-Pacific, and country-wise summaries of national legislation and policies.
  • Drug of abuse testing markets with respect to testing approaches and sample matrices.
  • Technology trends in the drug of abuse testing market.
  • Leading players in the market and their key products.
  • Sales projections through 2019 for drug of abuse testing markets by sample matrix and geographic regions.
  • Analysis of leading companies and their successful strategies.

ANALYST'S CREDENTIALS

Jon Evans has been involved in business development and research for the biotechnology industry since 1984. Mr. Evans' career includes four years as a diagnostic systems sales representative and more than 15 years in market research and strategy analysis with Fortune 500 clients. He has developed expertise in assessing the unique business development challenges facing firms in the biotechnology industry and designing strategies to optimize market performance. Mr. Evans received a B.S. in biology from Rutgers University in 1983, and an MBA in business analysis from San Francisco State University in 1989.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOAL AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, 2013-2019 ($ MILLIONS)

CHAPTER 3 - DRUGS OF ABUSE TESTING PRACTICES

  • SINGLE- VS MULTI-PARAMETER TEST
  • DOA SCREENING
  • CONFIRMATION TESTING
  • URINE TESTS
  • OTHER TESTING METHODS
    • BLOOD TESTING
    • ORAL FLUID TESTING
    • SALIVA TESTING
    • SWEAT TESTING
    • HAIR TESTING
  • TESTING LOCATIONS
    • LABORATORY-BASED DAT
      • Criminal Justice
        • Police
        • Prisons
        • Probation
      • Workplace Screening
      • Others
        • Military
        • Customs and Excise
        • Education
    • POINT OF CARE (POC) DATS
      • TABLE 1: ADVANTAGES AND DISADVANTAGES OF POINT OF CARE TESTING
    • ONSITE TESTING VS LABORATORY TESTING
      • TABLE 2: MAJOR ADVANTAGES AND DISADVANTAGES OF ONSITE TESTING
  • SAMPLE TYPES FOR LABORATORY TESTING
    • URINE TESTING
    • HAIR TESTING
    • SALIVA/ORAL FLUID TESTING
    • BLOOD TESTING
    • SWEAT TESTING
    • EYE REFLEX
  • DETECTION PERIOD
    • TABLE 3: DETECTION PERIODS FOR VARIOUS TYPES OF DRUG TESTING
  • FOOLING A DRUG TEST
    • FOOLING URINE TESTING
      • TABLE 4: COMMON PARAMETERS TESTED FOR URINE SPECIMEN VALIDITY
      • TABLE 5: SOME OF THE COMMERCIAL/COMMON ADULTERANTS USED IN FOOLING URINE TESTS AND THEIR EFFECTS
    • FOOLING HAIR TESTING
    • FOOLING SALIVA TESTING
  • SAMPLE VALIDITY TESTS
    • TABLE 6: URINE SAMPLE VALIDITY TEST METHODS
  • FALSE POSITIVES AND FALSE NEGATIVES
    • FALSE POSITIVES
      • TABLE 7: CROSS REACTANTS THAT CAN LEAD TO FALSE POSITIVES IN DOA TESTING
    • FALSE NEGATIVES
  • TESTING TECHNOLOGIES
    • IMMUNOASSAYS
    • ENZYME IMMUNOASSAY (EIA)
    • ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
    • ENZYME MULTIPLIED IMMUNOASSAY TECHNOLOGY (EMIT)
    • FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA)
    • RADIOIMMUNOASSAY (RIA)
    • CHROMATOGRAPHY
      • Gas Chromatography (GC)
      • High Performance Liquid Chromatography (HPLC)
      • Thin-Layer Chromatography (TLC)
      • Mass Spectrometry (MS)
      • Capillary Electrophoresis (CE)
      • Hyphenated MS/Chromatography
      • Gas-Chromatography-Mass Spectrometry (GC/MS)
    • EYE REFLEX MEASUREMENTS

CHAPTER 4 - GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG ABUSE TESTING

  • NORTH AMERICA
    • NATIONAL LEGISLATION AND POLICY
      • Canada
        • Drug Free Workplace
      • Mexico
      • The United States
        • Drug-Free Workplace
          • TABLE 8: U.S. DRUG TESTING LEGISLATIONS BY STATE, 2014
        • U.S. Department of Transportation
        • Drug Testing in the Military
        • Public Assistance Qualifications
          • Drug Testing for Individuals Convicted of Drug Felonies
        • 2014 Legislation
          • Legislative Proposals:
          • Legislative Enactments:
        • Quick Facts
        • 2013 Legislation
          • Legislative Proposals:
          • Legislative Enactments:
        • 2012 Legislation
        • Programs Included
        • 2011 Legislation
  • SOUTH AMERICA
    • NATIONAL LEGISLATION AND POLICY
      • Bolivia
      • Brazil
        • Drug-Free Workplace
      • Colombia
      • Ecuador
      • Guyana
      • Paraguay
      • Peru
  • CENTRAL AMERICA AND THE CARIBBEAN
    • NATIONAL LEGISLATION AND POLICY
      • Costa Rica
      • Cuba
      • El Salvador
      • Guatemala
      • Haiti
      • Jamaica
      • Nicaragua
      • Panama
      • Tegucigalpa
      • The Bahamas
      • The Netherlands Antilles
      • Trinidad and Tobago
  • EUROPE
    • NATIONAL LEGISLATION AND POLICY
      • Bosnia and Herzegovina
      • Denmark
      • France
      • Germany
      • Italy
      • Latvia
      • Norway
      • Romania
      • Sweden
      • Switzerland
      • The Netherlands
      • The United Kingdom
  • DRUG-FREE WORKPLACE POLICY AND LEGISLATION BY EUROPEAN COUNTRY
    • TABLE 9: DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008*
  • ASIA-PACIFIC
    • NATIONAL LEGISLATION AND POLICY
      • Australia
      • Bangladesh
      • Bhutan
      • Cambodia
      • Hong Kong
      • India
        • The NDPS (Regulation of Controlled Substances) Order, 1993
      • Japan
      • Maldives
      • Myanmar
      • Nepal
      • New Zealand
      • Singapore
      • South Korea
      • Sri Lanka
      • Taiwan
      • Thailand
      • Vietnam

CHAPTER 5 - OVERVIEW

  • DRUG ABUSE TESTING
    • INTRODUCTION
    • INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY DRUG TYPE
      • TABLE 10: NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003-2007 (MILLIONS)
      • Amphetamine-Type Stimulants Market
      • Cannabis Market
      • Coca/Cocaine Market
      • Opium/Heroin Market
    • INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY GEOGRAPHIC REGION
      • Africa
      • Central America and Caribbean
      • North America
        • TABLE 11: NORTH AMERICAN DOA SEIZURES, 2012
      • South America
      • East and Southeast Asia
      • South Asia
      • West Asia
      • Europe
        • TABLE 12: ANNUAL PREVALENCE OF OPIOID USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
        • TABLE 13: ANNUAL PREVALENCE OF COCAINE USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
        • TABLE 14: ANNUAL PREVALENCE OF CANNABIS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
        • TABLE 15: ANNUAL PREVALENCE OF ATS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
        • TABLE 16: ANNUAL PREVALENCE OF ECSTASY USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
      • Oceania
    • U.S. DRUGS OF ABUSE STATISTICS
      • National Household Survey on Drug Abuse: SAMHSA U.S.
        • Survey by Drug Type
          • TABLE 17: DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12 YRS AND OLDER), 2011 AND 2012 (THOUSANDS)
        • Survey by Age
          • TABLE 18: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY AGE, 2011 AND 2012 (THOUSANDS)
          • TABLE 19: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, RACE, AND ETHNICITY, 2011 AND 2012 (THOUSANDS)
        • Survey by Education and Current Employment Status
          • TABLE 20: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER BY GENDER, RACE, EDUCATION AND EMPLOYMENT, 2011 AND 2012 (THOUSANDS)

CHAPTER 6 - GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE MATRIX

  • DRUGS OF ABUSE TESTING SALES
    • TABLE 21: GLOBAL SALES CONTRIBUTION FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (%)
    • TABLE 22: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 ($ MILLIONS)
    • FIGURE 1: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2013-2019 ($ MILLIONS)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY URINE
    • TABLE 23: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 2: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2013-2019 ($ MILLIONS)
    • TABLE 24: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2014 (%)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY BLOOD
    • TABLE 25: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2019 ($ MILLIONS)
    • FIGURE 4: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2013-2019 ($ MILLIONS)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY ORAL FLUID
    • TABLE 26: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2013-2019 ($ MILLIONS)
    • TABLE 27: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2014 (%)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY HAIR
    • TABLE 28: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2013-2019 ($ MILLIONS)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY SWEAT
    • TABLE 29: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2013-2019 ($ MILLIONS)
  • GLOBAL SALES OF DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES
    • TABLE 30: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2019 ($ MILLIONS)
    • FIGURE 9: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2013-2019 ($ MILLIONS)

CHAPTER 7 - WORLDWIDE INDUSTRY STRUCTURE

  • REGIONAL ANALYSIS
    • FIGURE 10: DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGION, 2014 (%)
  • TOTAL DOA TESTING AND DRUG MONITORING MARKETS AND FORECASTS
    • TABLE 31: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, THROUGH 2019 ($ MILLIONS)
  • GROWTH TRENDS-LABORATORY-BASED AND ONSITE DOA TESTING MARKETS
    • LABORATORY-BASED DOA TESTING MARKETS AND FORECASTS
      • TABLE 32: DRUGS OF ABUSE TESTING MARKET FORECAST FOR
  • LABORATORY-BASED TESTING, THROUGH 2019 ($ MILLIONS)
    • ONSITE DOA TESTING MARKETS AND FORECASTS
      • TABLE 33: DRUGS OF ABUSE TESTING MARKET FORCAST FOR ONSITE TESTING, THROUGH 2019 ($ MILLIONS)
    • COMPETITIVE ANALYSIS
      • TABLE 34: MOST NOTABLE MERGERS AND ACQUISITIONS IN THE DOA TESTING MARKETS, 2000-2012
    • KEY MARKET PLAYERS IN THE DOA TESTING MARKETS AND THEIR PRODUCTS
      • TABLE 35: MAJOR COMPANIES AND THEIR PRODUCTS IN THE DOA TESTING MARKET
    • LABORATORY-BASED DOA TESTING MARKET SEGMENT
      • TABLE 36: COMPANIES OFFERING LABORATORY-BASED DOA TESTING PRODUCTS
    • ONSITE TESTING MARKET SEGMENT FOR DOA
      • TABLE 37: MAIN ONSITE DOA TESTING MARKET PLAYERS AND THEIR PRODUCTS
    • COMMON DRUGS OF ABUSE AND MOST POPULAR DEVICES USED FOR TESTING THEM
      • TABLE 38: COMMON DOA AND POPULAR URINE DRUG SCREENING PRODUCTS
    • COMPANIES IN THE ORAL FLUID, HAIR, AND SWEAT TESTING SEGMENTS FOR DOA
      • TABLE 39: KEY MARKET PLAYERS OFFERING DOA TESTING PRODUCTS ON ORAL FLUID, HAIR AND SWEAT SAMPLE MATRICES

CHAPTER 8 - PATENT ANALYSIS

  • TABLE 40: U.S. DRUGS OF ABUSE TESTING PATENTS BY PATENT NUMBER AND TITLE, 2007-2014
  • TABLE 41: U.S. DRUGS OF ABUSE TESTING PATENTS BY ASSIGNEE, 1978-2007

CHAPTER 9 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACON LABORATORIES INC.
  • AGILENT TECHNOLOGIES
  • ALERE INC.
  • AMERICAN BIO MEDICA CORP. (ABMC)
  • BECKMAN COULTER
  • BIO-RAD LABORATORIES, INC
  • CONCATENO, PLC
  • ELITECH GROUP
  • F. HOFFMANN-LA ROCHE LTD.
  • MEDTOX DIAGNOSTICS
  • MICROGENICS
  • NANOGEN INC.
  • OLYMPUS DIAGNOSTICS SYSTEMS
  • ORASURE TECHNOLOGIES INC.
  • ORTHO-CLINICAL DIAGNOSTICS
  • SIEMENS HEALTHCARE DIAGNOSTICS INC.

CHAPTER 10 - APPENDIX A

  • TABLE 42: GLOSSARY OF COMMON TERMS
  • TABLE 43: GLOSSARY OF SCIENTIFIC ABBREVIATIONS
  • TABLE 44: ASSOCIATIONS

CHAPTER 11 - APPENDIX B

  • TABLE 45: DOA SEIZURES IN EUROPE, 2012

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: ADVANTAGES AND DISADVANTAGES OF POINT OF CARE TESTING
    • TABLE 2: MAJOR ADVANTAGES AND DISADVANTAGES OF ONSITE TESTING
    • TABLE 3: DETECTION PERIODS FOR VARIOUS TYPES OF DRUG TESTING
    • TABLE 4: COMMON PARAMETERS TESTED FOR URINE SPECIMEN VALIDITY
    • TABLE 5: SOME OF THE COMMERCIAL/COMMON ADULTERANTS USED IN FOOLING URINE TESTS AND THEIR EFFECTS
    • TABLE 6: URINE SAMPLE VALIDITY TEST METHODS
    • TABLE 7: CROSS REACTANTS THAT CAN LEAD TO FALSE POSITIVES IN DOA TESTING
    • TABLE 8: U.S. DRUG TESTING LEGISLATIONS BY STATE, 2014
    • TABLE 9: DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008*
    • TABLE 10: NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003-2007 (MILLIONS)
    • TABLE 11: NORTH AMERICAN DOA SEIZURES, 2012
    • TABLE 12: ANNUAL PREVALENCE OF OPIOID USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
    • TABLE 13: ANNUAL PREVALENCE OF COCAINE USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
    • TABLE 14: ANNUAL PREVALENCE OF CANNABIS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
    • TABLE 15: ANNUAL PREVALENCE OF ATS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
    • TABLE 16: ANNUAL PREVALENCE OF ECSTASY USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR
    • TABLE 17: DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12 YRS AND OLDER), 2011 AND 2012 (THOUSANDS)
    • TABLE 18: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY AGE, 2011 AND 2012 (THOUSANDS)
    • TABLE 19: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, RACE, AND ETHNICITY, 2011 AND 2012 (THOUSANDS)
    • TABLE 20: ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER BY GENDER, RACE, EDUCATION AND EMPLOYMENT, 2011 AND 2012 (THOUSANDS)
    • TABLE 21: GLOBAL SALES CONTRIBUTION FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (%)
    • TABLE 22: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 ($ MILLIONS)
    • TABLE 23: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2019 ($ MILLIONS)
    • TABLE 24: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 ($ MILLIONS)
    • TABLE 25: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2019 ($ MILLIONS)
    • TABLE 26: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2019 ($ MILLIONS)
    • TABLE 27: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2019 ($ MILLIONS)
    • TABLE 30: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2019 ($ MILLIONS)
    • TABLE 31: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 32: DRUGS OF ABUSE TESTING MARKET FORECAST FOR LABORATORY-BASED TESTING, THROUGH 2019 ($ MILLIONS)
    • TABLE 33: DRUGS OF ABUSE TESTING MARKET FORCAST FOR ONSITE TESTING, THROUGH 2019 ($ MILLIONS)
    • TABLE 34: MOST NOTABLE ME: GERS AND ACQUISITIONS IN THE DOA TESTING MARKETS, 2000-2012
    • TABLE 35: MAJOR COMPANIES AND THEIR PRODUCTS IN THE DOA TESTING MARKET
    • TABLE 36: COMPANIES OFFERING LABORATORY-BASED DOA TESTING PRODUCTS
    • TABLE 37: MAIN ONSITE DOA TESTING MARKET PLAYERS AND THEIR PRODUCTS
    • TABLE 38: COMMON DOA AND POPULAR URINE DRUG SCREENING PRODUCTS
    • TABLE 39: KEY MARKET PLAYERS OFFERING DOA TESTING PRODUCTS ON ORAL FLUID, HAIR AND SWEAT SAMPLE MATRICES
    • TABLE 40: U.S. DRUGS OF ABUSE TESTING PATENTS BY PATENT NUMBER AND TITLE, 2007-2014
    • TABLE 41: U.S. DRUGS OF ABUSE TESTING PATENTS BY ASSIGNEE, 1978-2007
    • TABLE 42: GLOSSARY OF COMMON TERMS
    • TABLE 43: GLOSSARY OF SCIENTIFIC ABBREVIATIONS
    • TABLE 44: ASSOCIATIONS
    • TABLE 45: DOA SEIZURES IN EUROPE, 2012

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, 2013-2019 ($ MILLIONS)
    • FIGURE 1: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2013-2019 ($ MILLIONS)
    • FIGURE 2: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2013-2019 ($ MILLIONS)
    • FIGURE 3: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2014 (%)
    • FIGURE 4: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2013-2019 ($ MILLIONS)
    • FIGURE 5: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2013-2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2014 (%)
    • FIGURE 7: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2013-2019 ($ MILLIONS)
    • FIGURE 8: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2013-2019 ($ MILLIONS)
    • FIGURE 9: GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2013-2019 ($ MILLIONS)
    • FIGURE 10: DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGION, 2014 (%)
Back to Top